Kairos Pharma (KAPA) Q1 2026 Annual Earnings
KAPA·Reported May 13, 2026·Before market open
Diluted EPS came in at $-0.08 (+0.0% YoY), missed the $-0.07 consensus by $0.01.
Diluted EPS
$-0.08missed by $0.01
Consensus: $-0.07
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Kairos Pharma's Q1 2026 earnings report.
Kairos Pharma (KAPA) reported Q1 2026 earnings on May 13, 2026 before market open.
Kairos Pharma reported diluted EPS of $-0.08 for Q1 2026.
EPS missed the consensus estimate of $-0.07 by $0.01.
Compared to the same quarter a year prior, diluted EPS grew 0.0% from $-0.08.
You can read the 10-K periodic report (0001493152-26-014159) directly on SEC EDGAR. The filing index links above go to sec.gov.